What’s recent research saying about the use of tomosynthesis versus conventional 2D digital mammography to screen for breast cancer? Find out with Dr. Manisha Bahl, a breast imaging radiologist and Assistant Professor of Radiology at Harvard Medical Center.

There are different treatment options available for early-stage mesothelioma, and there seem to be differences in standard practice from one center to the next. Joining Dr. Jacob Sands to share how he approaches the treatment of early-stage mesothelioma using the latest options is Dr. Aaron Mansfield, an Associate Professor of Oncology and Co-Director of Precision Cancer Therapeutics at Mayo Clinic in Rochester.

What do the updated prevention and risk screening strategies for breast cancer look like in practice? Here to share how the MD Anderson Cancer Center at Cooper University Health Care has adopted those strategies is Dr. Pallav Mehta.

What do the updated prevention and risk screening strategies for breast cancer look like in practice? Here to share how the MD Anderson Cancer Center at Cooper University Health Care has adopted those strategies is Dr. Pallav Mehta.

What is the role of autoantibodies in breast cancer detection? Dr. Pallav Mehta, the Director of Integrative Oncology and Practice Development at the MD Anderson Cancer Center at Cooper University Health Care, shares the latest research on autoantibodies as potential biomarkers in the early detection of breast cancer.

Dr. Pavani Chalasani, Associate Professor of Medicine and Program Director of the Hematology/Oncology Fellowship at the University of Arizona Cancer Center, discusses the utility of prognostic markers to improve outcomes for patients with breast cancer.

Dr. Pavani Chalasani, Associate Professor of Medicine and Program Director of the Hematology/Oncology Fellowship at the University of Arizona Cancer Center, examines current clinical trials investigating the role of CDK 4/6 inhibitors in early stage HER positive and HER2 negative breast cancer treatment.

Dr. Pavani Chalasani, Associate Professor of Medicine and Program Director of the Hematology/Oncology Fellowship at the University of Arizona Cancer Center, examines current clinical trials investigating the role of CDK 4/6 inhibitors in early stage HER positive and HER2 negative breast cancer treatment.

Dr. Pavani Chalasani, Associate Professor of Medicine and Program Director of the Hematology/Oncology Fellowship at the University of Arizona Cancer Center, discusses the utility of prognostic markers to improve outcomes for patients with breast cancer.

What are some of the most recent advancements in RET diagnostics? Dr. Balazs Halmos discusses molecular testing for patients with non-small cell lung cancer, or NSCLC, and best practices to use when treating patients with RET alterations.